<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971724</url>
  </required_header>
  <id_info>
    <org_study_id>P05888</org_study_id>
    <secondary_id>294001</secondary_id>
    <nct_id>NCT00971724</nct_id>
  </id_info>
  <brief_title>Biomarkers of Prednisolone Treatment (P05888)</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Single-center Study Using Multiple Doses of Prednisolone to Quantify Effects on Selected Biomarkers and Assess Pharmacokinetics in Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

        -  To identify a biomarker or biomarker-set for the adverse metabolic effects of various
           doses of prednisolone treatment.

      Secondary objectives:

        -  To describe the PK of prednisolone and PD of a series of biomarkers.

        -  To identify biomarkers that reflect side effects of prednisolone.

        -  To elucidate part of the mechanisms by which prednisolone induces metabolic changes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identify a biomarker or biomarker-set for adverse metabolic effects of various doses of prednisolone</measure>
    <time_frame>Day 1 and day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the PK of prednisolone and PD of a series of biomarkers</measure>
    <time_frame>Day 1 and day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Hyperglycemia</condition>
  <condition>Glucose Intolerance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with placebo for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone 7.5 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with prednisolone 7.5 mg daily for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone 15 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with prednisolone 15 mg daily for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone 30 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with prednisolone 30 mg daily for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with prednisolone 75 mg for a single day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone 15 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with prednisolone 15 mg twice daily for a single day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration, once daily, for 15 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Prednisolone 7.5 mg daily</arm_group_label>
    <arm_group_label>Prednisolone 15 mg daily</arm_group_label>
    <arm_group_label>Prednisolone 30 mg daily</arm_group_label>
    <arm_group_label>Prednisolone 75 mg</arm_group_label>
    <arm_group_label>Prednisolone 15 mg twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  22 &lt; BMI &lt; 30

          -  fasting glucose &lt; 5.6 mmol/L and glucose &lt; 7.8 mmol/L 2hr after OGTT

          -  able and willing to sign informed consent

          -  history of good physical and mental health

          -  subject smokes less than 5 cigarettes per day

          -  able to keep a normal day and night rhythm

        Exclusion Criteria:

          -  allergy to prednisolone

          -  glucocorticoid use during last 3 months prior to study

          -  use of any drug or substance

          -  history of familiar diabetes type 2

          -  clinically relevant history or presence of any medical disorder

          -  clinically relevant abnormal lab or ECG

          -  positive drug or alcohol screen, positive hepatitis B or C surface antigen

          -  donation of blood (&gt;100 mL) within 90 days prior to the first dose
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prednisolone</keyword>
  <keyword>Glucocorticoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

